Netilmicin in the neonate: pharmacokinetic analysis and influence of parenteral nutrition

Bacopoulou, Flora; Skouroliakou, Maria; Markantonis, Sophia L.

doi:10.1007/s11096-009-9278-z

Cited by 8 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some investigations have demonstrated the absence of significant changes in the plasma concentrations of the antibiotic netilmicin in children fed by PN. (4) …”

Section: Discussionmentioning

confidence: 99%

Drug-nutrient interactions in the intensive care unit: literature review and current recommendations

Heldt¹,

Loss²

2013

Revista Brasileira De Terapia Intensiva

View full text Add to dashboard Cite

ObjectiveTo describe the interactions between drugs and nutrients and their frequency in the intensive care unit and to assess the professional team's awareness regarding this subject.MethodsThe keywords "drug interactions" and "nutrition therapy" were searched in the PubMed (specifically MeSH) electronic database. The studies were systematically reviewed for descriptions of the types of interactions between drugs and nutrients, including their frequency and consequences. ResultsSixty-seven articles were found. Among these, 20 articles were appropriate for the methodology adopted and accomplished the objectives of the study. Of these 20 articles, 14 articles described interactions between drugs and enteral nutrition, three described interactions between drugs and parenteral nutrition, and three described the importance and care required to avoid such interactions.ConclusionsThe literature about drug and nutrient interactions is limited and suggests the inability of health care teams to recognize the potential for these interactions. Possibly, the elaboration of a protocol to evaluate drug-nutrient interactions will increase the safety and efficacy of therapeutics.

show abstract

“…Some investigations have demonstrated the absence of significant changes in the plasma concentrations of the antibiotic netilmicin in children fed by PN. (4) …”

Section: Discussionmentioning

confidence: 99%

Drug-nutrient interactions in the intensive care unit: literature review and current recommendations

Heldt¹,

Loss²

2013

Revista Brasileira De Terapia Intensiva

View full text Add to dashboard Cite

show abstract

“…Netilmicin sulfate is another semisynthetic aminoglycoside antibiotic derived from sisomicin. It is used for the treatment of P. aeruginosa infections in cystic fibrosis (Prayle & Smyth, 2010 ), neonatal sepsis (Bacopoulou et al, 2009 ), and Septic Burn Patients (Munster, 1979 ). It has also been demonstrated that the entrapment of netilmicin sulfate in poly(DL-lactide-co-glycolide) (PLGA) hydrophobic matrix enhanced its bioavailability, reduce dosing frequency, and side effects (Kolate et al, 2015 ).…”

Section: Antibiotics Against Multiple Therapeutic Targets Of Sars-cov-2mentioning

confidence: 99%

Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications

Naik

Mattaparthi

Gupta

et al. 2021

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

In view of many European countries and the USA leading to the second wave of COVID-19 pandemic, winter season, the evolution of new mutations in the spike protein, and no registered drugs and vaccines for COVID-19 treatment, the discovery of effective and novel therapeutic agents is urgently required. The degrees and frequencies of COVID-19 clinical complications are related to uncontrolled immune responses, secondary bacterial infections, diabetes, cardiovascular disease, hypertension, and chronic pulmonary diseases. It is essential to recognize that the drug repurposing strategy so far remains the only means to manage the disease burden of COVID-19. Despite some success of using single-target drugs in treating the disease, it is beyond suspicion that the virus will acquire drug resistance by acquiring mutations in the drug target. The possible synergistic inhibition of drug efficacy due to drug-drug interaction cannot be avoided while treating COVID-19 and allied clinical complications. Hence, to avoid the unintended development drug resistance and loss of efficacy due to drug-drug interaction, multi-target drugs can be promising tools for the most challenging disease. In the present work, we have carried out molecular docking studies of compounds from the FDA approved drug library, and the FDA approved and passed phase −1 drug libraries with ten therapeutic targets of COVID-19. Results showed that known drugs, including nine anti-inflammatory compounds, four antibiotics, six antidiabetic compounds, and one cardioprotective compound, could effectively inhibit multiple therapeutic targets of COVID-19. Further in-vitro , in vivo , and clinical studies will guide these drugs' proper allocation to treat COVID-19. Communicated by Ramaswamy H. Sarma

show abstract

“…Critically ill neonates given netilmicin along with fluid therapy or parenteral nutrition during the first week of life had a mean V D of 0.46–0.53 L/kg, half-life of 6.8–12.8 hours, and CL of 0.03–0.05 L/hr/kg [116]. There was no statistically significant difference between the PK parameters of netilmicin among neonates receiving either fluid therapy or parenteral nutrition [116]. Non-critically ill newborns had a slightly smaller mean V D (0.41–0.52 L/kg), a shorter mean half-life (4.6–8.5 hours) and similar mean CL (0.04–0.06 L/hr/kg) [117–119].…”

Section: Pharmacokinetic Studies In Critically Ill Childrenmentioning

confidence: 99%

“…Non-critically ill newborns had a slightly smaller mean V D (0.41–0.52 L/kg), a shorter mean half-life (4.6–8.5 hours) and similar mean CL (0.04–0.06 L/hr/kg) [117–119]. The slightly higher V D in critically ill neonates was possibly due to an expansion of the extracellular compartment from the hypertonic osmotic load administered during parenteral nutrition [116]. Another study performed in critically ill children (1 day to 15.5 years of age) reported that the majority (65%) of children with elevated trough levels had acute onset of renal insufficiency [120].…”

Section: Pharmacokinetic Studies In Critically Ill Childrenmentioning

confidence: 99%

Clinical Pharmacology Studies in Critically Ill Children

et al. 2016

View full text Add to dashboard Cite

Developmental and physiological changes in children contribute to variation in drug disposition with age. Additionally, critically ill children suffer from various life-threatening conditions that can lead to pathophysiological alterations that further affect pharmacokinetics (PK). Some factors that can alter PK in this patient population include variability in tissue distribution caused by protein binding changes and fluid shifts, altered drug elimination due to organ dysfunction, and use of medical interventions that can affect drug disposition (e.g., extracorporeal membrane oxygenation and continuous renal replacement therapy). Performing clinical studies in critically ill children is challenging because there is large inter-subject variability in the severity and time course of organ dysfunction; some critical illnesses are rare, which can affect subject enrollment; and critically ill children usually have multiple organ failure, necessitating careful selection of a study design. As a result, drug dosing in critically ill children is often based on extrapolations from adults or non-critically ill children. Dedicated clinical studies in critically ill children are urgently needed to identify optimal dosing of drugs in this population. This review will summarize the effect of critical illness on pediatric PK, the challenges associated with performing studies in this vulnerable subpopulation, and the clinical PK studies performed to date for commonly used drugs.

show abstract

Netilmicin in the neonate: pharmacokinetic analysis and influence of parenteral nutrition

Abstract: Provision of parenteral nutrition (versus fluid therapy) in critically ill neonates >32 weeks did not significantly affect netilmicin pharmacokinetics and therefore does not require modification of recommended netilmicin dosage regimens.

Cited by 8 publications

References 9 publications

Drug-nutrient interactions in the intensive care unit: literature review and current recommendations

Drug-nutrient interactions in the intensive care unit: literature review and current recommendations

Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications

Clinical Pharmacology Studies in Critically Ill Children

Contact Info

Product

Resources

About